HLS’s VASCEPA Shows Promise for Heart Disease Patients

Hls Therapeutics (TSE:HLS) has released an update.

HLS Therapeutics Inc. has announced findings from the REDUCE-IT clinical trial, revealing that their drug VASCEPA significantly reduces the risk of major adverse cardiovascular events (MACE) in patients with high or low Lipoprotein(a) levels. The analysis, which also featured in the Journal of the American College of Cardiology, shows that VASCEPA offers a consistent treatment benefit across different patient subgroups, regardless of their baseline LDL-C or triglyceride levels.

For further insights into TSE:HLS stock, check out TipRanks’ Stock Analysis page.